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EDITORIAL 
First birth following spindle transfer for mitochondrial replacement 
therapy: hope and trepidation 
 
In this issue, Zhang et al. (2017) report the birth of a healthy boy after 
mitochondrial replacement therapy (MRT) by spindle transfer to prevent 
transmission of mitochondrial disease from mother to child. The case was 
first publicized in the lay press (Hamzelou, 2016; see also editorial by 
Johnson, 2016) and then presented during the 2016 Annual Meeting of the 
American Society for Assisted Reproduction (ASRM) in October 2016 (Zhang 
et al., 2016b). It followed an earlier report of an unsuccessful attempt at 
MRT by pronuclear transfer by the same group (Zhang et al., 2016a). This 
world-first birth represents an achievement and a steppingstone, and it has 
played a role in encouraging the Human Fertilization and Embryology 
Authority (HFEA) in the UK to issue a final recommendation that the 
technique 'be approved for cautious use in specific circumstances'. 
(http://www.hfea.gov.uk/10559.html) 
 
We, the editors, were unanimous in deciding that this paper should be 
published in RBMO, based on our conviction that the scientific community 
must be informed of the details of the work in full in order to evaluate it 
critically and discuss it openly. We decided this despite the fact that the 
work has weaknesses and limitations in a number of areas. Moreover, 
although we were able to encourage the authors to include more details of 
their work in the submission, some uncertainties concerning methodologies 
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and results still remain.  Here we outline our concerns regarding the 
approach and the treatment process described by Zhang and colleagues.  
 
IRB approval, informed consent, and follow-up plans  
The patient’s treatment was carried out at two locations. While the ovarian 
stimulation cycles and oocyte manipulations were carried out at a private 
fertility clinic in New York, the vitrified embryo was then shipped to Mexico 
to be warmed and transferred to the patient at an affiliate clinic in 
Guadalajara. The authors received approval from the Internal Review Board 
(IRB) of the Mexican clinic for transfer of a 'euploid embryo resulting from 
cell reconstruction'. The Board also approved a general protocol that 
included spindle transfer, oocyte reconstitution, intra-cytoplasmic sperm 
injection (ICSI), and preimpantation genetic screening (PGS). However, no 
IRB approval for these procedures was applied for in the clinic in New York, 
contrary to the recommendations of the American Medical Association 
regarding international research (AMA, 2010). Moreover, the 
accompanying Mexican consent form discussed MRT only in a superficial 
manner, stating that transfer of the meiotic spindle is intended for 
correction of cytoplasmic disorders, one objective of which 'can be 
extended to cancel or reduce the risk of mitochondrial disease' The consent 
form appropriately stated that 'cell stage reconstruction' through 
cytoplasmic replacement is considered an 'experimental procedure' but 
while alternative options to this treatment were listed, risks specific to 
mitochondrial replacement were not included. The authors explain that the 
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patient received extensive counselling over the course of several years, but 
the final consent form does not record this.  
 
Although the egg donor reportedly signed a standard egg donor consent 
form, a copy of this form received by RBMO shows that the use of the 
donated eggs specifically for spindle transfer (for MRT) is not mentioned.  
 
The authors detail their comprehensive plans for follow up of the child, 
including physical examination every 3 months during the first year and 
every 6 months during the second year, then annually until age 18, 
followed by fertility and other assessments after age 18. They state that the 
patient has agreed to these plans. Indeed, the patient did provide informed 
consent to testing of neonatal tissues, as well as to follow up 'physical 
examinations' of the child, although the nature of these examinations or 
their frequency was not included in the consent form or in the IRB protocol. 
On the other hand, we understand that signing a consent form does not 
bind a patient to agree subsequently to often-intrusive medical follow-up 
studies (Johnson, 2016). Indeed, informed consent provides for the right of 
any subject to 'discontinue participation [in a study] at any time without 
penalty or loss of benefits to which the subject is otherwise entitled' (US 
Department of Health and Human Services, 2010) unless early withdrawal 
threatens adverse effects, in which case these should be described in the 
consent form. However, we noted that potential adverse effects of MRT 
were not described in the consent form signed by the patient. Moreover, 
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examination of the patient's child after age 18 would require the child's 
explicit consent, which may or may not be provided. 
 
Thus, although the requirements for IRB review and approval of this 
experimental procedure, as well as informed consent, were generally met, 
the shortcomings of the process may be considered significant and should 
be fully addressed in future cases.  
 
Patient screening and selection 
The 36-year-old patient is a carrier of mitochondrial DNA mutation 8993 
T>G, which causes Leigh syndrome. She was appropriately tested and was 
found to be heteroplasmic with 23%, 24% and 33% pathogenic mtDNA in 
her hair follicles, blood and urine, respectively. The family pedigree was 
also examined; the patient has two deceased affected siblings, and one 
sibling with 4 affected children. Although she is asymptomatic, she has 
suffered the devastating death of two of her children at ages 8 months and 
6 years from Leigh syndrome.  She has also experienced a number of 
miscarriages, though these were not diagnosed as being due to Leigh 
syndrome. Thus the authors met the requirement for careful patient 
screening and selection prior to initiating treatment, though no testing was 
done in the extended family. 
 
Preclinical work and treatment details 
The authors report that the patient underwent two minimal ovarian 
stimulation cycles. Mature oocytes from the first cycle were vitrified until 
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the second cycle was attempted, at which time they were warmed and, 
along with the fresh oocytes, were available for use in MRT. Donor oocytes 
were also vitrified and warmed. The impact of vitrification and warming of 
patient and donor oocytes on the outcome of spindle transfer has not been 
fully investigated. In the study of Kang et al. (2016), 4 of 6 reconstructed 
oocytes using vitrified cytoplasm (donor oocytes) with fresh spindles 
(patient oocytes) fertilized normally and 1 of 4 formed a normal blastocyst. 
By comparison, 2 of 6 reconstructed oocytes using vitrified spindles (patient 
oocytes) with fresh cytoplasm (donor oocytes) fertilized normally and one 
of 2 formed a normal blastocyst. The small sample sizes do not permit a 
clear interpretation, although the results perhaps suggest that vitrification 
and warming have minimal effect on the procedure. In the case reported by 
Zhang et al. (2017), no embryos resulted from vitrified patient oocytes and 
the transferred embryo was from fresh spindle transfer into vitrified-
warmed cytoplast. 
 
Of the 29 oocytes retrieved from the patient during two cycles, only 9 were 
found to be mature and even fewer showed birefringent spindles when 
examined by polarized light microscopy. A total of 15 oocytes were 
described as 'degenerate'. The reason for such a high incidence of 
degeneration is unknown. Zhang et al. (2017) do not discuss oocyte quality 
in any depth, but a recent study by Kang et al. (2016) noted lower peak 
oestradiol concentration and fewer oocytes from carriers of mitochondrial 
disease compared with donors. Kang and colleagues (2016) point to 
collection of only atretic eggs in one Leigh syndrome carrier patient and 
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although they cite elevated progesterone prior to HCG administration to 
explain this outcome, it is conceivable that oogenesis and follicular 
development in women carrying pathogenic mitochondrial DNA is 
impaired.  Based on the reports from Kang et al. (2016) and Zhang et al. 
(2017) on Leigh syndrome patients, it could also be postulated that 
completion of maturation in normal oocytes is under the control of 
ooplasmic mitochondria, whereas the early growth of immature oocytes is 
not.  This is both interesting and surprising, and requires further research.  
It also shows that simply discarding atretic oocytes, without determining 
mtDNA mutation rates in the cytoplasm, is a waste of potentially useful 
material.  
 
According to the authors, this is the first and only clinical MRT case 
performed by the group, and the approach taken was based on experience 
gained and experimental data obtained over the last two decades by the 
authors and others. A number of these publications are cited. Included in 
their pre-clinical studies are limited data that suggest a 'modified 
electrofusion' technique does not lead to increased aneuploidy levels 
following human pronuclear transfer (PNT) (Liu et al., 2015). But it is not 
clear how modifications such as opening the zona pellucida using laser 
ablation (rather than zona dissection) and spindle transfer at 37°C (rather 
than at room temperature) can address concerns with electrofusion, as the 
authors do not present any experimental data to support their claim.  
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Indeed, in the present case, 3 of the 4 biopsied and tested blastocysts were 
found to be aneuploid by array CGH. Aneuploidy rate is age dependent and 
can vary from cycle to cycle during assisted reproduction; thus it is difficult 
to know whether or not electrofusion contributed to aneuploidy in this 
case. However, a number of authors have suggested that using an electrical 
pulse is not the preferred method for transfer of spindles, noting that the 
process may lead to premature activation of the human oocyte and later, 
abnormal pronuclear formation (Tachibana et al., 2013). It has been argued 
that this problem would be avoided if fusion were facilitated via the use of 
Sendai virus (Tachibana et al., 2009) or if manipulations were performed in 
a Ca2+ -free medium (Tachibana et al., 2013). On the other hand, Paull et al. 
(2013) suggested that premature activation and aneuploidy could be 
avoided by shortening the interval between ovulation trigger and oocyte 
retrieval and by short exposure of the spindle to room temperature prior to 
electrofusion; the latter suggestion is surprising given that lowering the 
temperature leads to rapid spindle disassembly (Pickering et al., 1990), 
which apparently was the intention of the investigators. Yet, convincing 
proof that any of these approaches are safe for use in nuclear transfer in 
the human seems to be lacking. Using Sendai virus for spindle fusion, Kang 
et al (2016) found 2 of 6 blastocysts to be euploid – an outcome rather 
similar to the results of Zhang et al. (2017). Thus the question of the best 
methodology for fusion of nuclei/spindles is still open to debate. 
 
Mutation load and mutant mtDNA carryover  
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The authors did not test directly the enucleated oocytes of the patient for 
mutation load and only arrived at their conclusion that the mutation load 
was 100% through calculation. Given Kang and colleagues' report (2016) of 
a mutation load varying from 0.6% to 100% in tested cytoplasts from carrier 
patients, this is clearly a weakness of the experimental design by Zhang et 
al. (2017) and one that should be addressed in future attempts. 
 
The blastocyst that was transferred to the patient showed a 5.7% mutation 
load. This is a higher carryover load than that reported by other groups, but 
it is unknown whether these differences could be partly due to differences 
in sensitivity and accuracy of the assays used in the different studies. 
Tachibana et al. (2009) reported nearly homoplasmic offspring following 
spindle transfer in the monkey, and Kang et al. (2016) obtained human 
embryos after spindle transfer with <1% mutant maternal mtDNA. 
However, the latter also report gradual loss of donor mtDNA and a full 
reversion to the maternal haplotype in embryonic stem cells derived from 
these embryos after multiple passages in vitro. Although 'reversion' is a 
significant concern, as Zhang et al. (2017) discuss, it is not known whether 
the mechanisms underlying reversion in embryonic stem cells in vitro are 
also operative in vivo in humans. Thus long-term follow up of children 
resulting from MRT is crucial. 
 
Outlook for the child   
According to the authors, the child, who was 7 months old at the time of 
reporting, is healthy. The mutation load varied in the newborn baby’s 
 9 
tissues, the lowest level of 2.36% having been found in the urine precipitate 
and the highest level of 9.23% in the circumcised foreskin. The level of 
heteroplasmy is a key issue in MRT since high levels can lead to 
manifestation of disease.  The question of whether mutation load increases 
with increasing age is one that cannot be answered definitively at this 
point. Only follow up of this child and other children to be born from MRT 
will provide that answer. A survey-based follow up of 17 children, ranging 
in age from 13 to 18 years, born following cytoplasmic transplantation in 
the 1990s was recently published (Chen et al., 2016) and included two 
children in whom testing after birth had shown presence of both normal 
donor and maternal mitochondria (Barritt et al., 2001). These children 
reportedly remain healthy (Chen et al., 2016) but it should be noted that 
repeated testing of the proportions of donor and maternal mitochondria in 
the young adults was not performed, consistent with the wishes of the 
families. Indeed, in the case reported here also, the family has requested 
that no further testing for mutant mtDNA load be undertaken, unless there 
is a clinical benefit.  
 
Cross-border MRT?  
In the UK, the Human Fertilisation and Embryology (HFE) Act of 1990 was 
amended in 2008 to allow for regulations to be passed that would permit 
techniques that prevent the transmission of serious mitochondrial disease 
due to deleterious mutations in mtDNA. In 2011, the UK Government asked 
the HFEA to examine the safety and efficacy of these techniques and in 
response the HFEA established a scientific panel, with broad-ranging 
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scientific and clinical expertise, to examine the evidence (HFEA, 2011). In 
addition, the HFEA was asked in January 2012 to carry out a public dialogue 
on the social and ethical impact of making these techniques available to 
patients (HFEA, 2012). Two further panel reviews were carried out in 2013 
and 2014 (HFEA, 2013, 2014). In February 2015, following extensive debate, 
the UK House of Commons approved the enabling regulations, which came 
into force on 29 October 2015. The HFEA published a fourth panel report in 
November 2016 (HFEA, 2016) recommending careful application of the 
technology to select patients. This recommendation was adopted by the 
HFEA on the 15 December 2016, thereby enabling licensed fertility clinics in 
the UK to apply to the HFEA for a license to perform mitochondrial 
donation treatment. In addition, the Nuffield Council on Bioethics 
published a comprehensive report on the ethics of mitochondrial donation 
(Nuffield, 2012). Thus, the UK has engaged in a deliberative and democratic 
– if perhaps unduly protracted  – process, having taken 8 years to arrive at 
its current position. 
 
In the USA, the picture is much less clear. In July 2001, prompted by the 
cytoplasmic transfer studies that took place in the 1990s (Cohen et al., 
1997; 1998), the Center for Biologics Evaluation and Research (CBER) of the 
US Food and Drug Administration (FDA) exercised its jurisdiction over 'cell 
and gene therapy products' and informed ART clinics of a requirement for 
an Investigational New Drug (IND) application for 'therapy involving the 
transfer of genetic material by means other than the union of gamete 
nuclei' (Johnson, 2016). More recently, in a move toward approving MRT, 
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and following an advisory committee’s recommendations in 2014 (FDA, 
2014), the FDA commissioned a report by the Institute of Medicine (IOM), 
the conclusions of which were positive toward MRT technologies and their 
purpose (Cohen and Adashi, 2016). Most unfortunately, in December 2015, 
before publication of the IOM report, a federal statute, added to an 
appropriations bill, essentially prohibited the FDA from considering such 
applications, bringing progress in this area to a halt (Cohen and Adashi, 
2016).  
 
In the case described here, the MRT embryos were generated in New York 
through privately funded research, but the therapeutic part of the 
procedure – that is, transfer of the embryo to the patient – was done at an 
affiliated clinic in Mexico, thereby technically circumventing the federal 
statute. In response to questions raised by referees regarding the legal 
framework for their work, Zhang et al. (2017) shared with RBMO editors a 
pre-IND review request to the FDA, in which they described their past work 
and desire to continue to offer MRT to selected patients in the USA. 
However, bound by the December 2015 statute, the FDA apparently 
declined the investigators’ request to meet or consider their application.   
 
It is unfortunate that in this first attempt at MRT, investigators whose 
primary practice is in the USA found it necessary to resort to a clinic in a 
non-regulated jurisdiction. Such an action is open to criticism on many 
fronts, particularly the charge that it constitutes exploitation of vulnerable 
patients. Conversely, criticism of the use of the Mexican clinic lays one 
 12 
open to the charge of prejudice or ethical and cultural imperialism 
(Editorial, 2016), as it could rightly be argued that Mexico could have also 
passed laws against MRT had it wished to. Indeed, Palacios González (2016) 
has commented that the fact of this clinic having been used may favour the 
passage of very conservative legislation that is currently being considered 
by Mexico, but this not a certain outcome.  
 
As outlined in a recent ASRM Ethics Committee opinion (ASRM, 2016), 
cross-border reproductive care (CBRC) is a growing reality in ART, 
motivated by a range of issues (Gurtin and Inhorn, 2011). When the 
purpose of CBRC is to evade the law, some argue in favour of tolerance 
(Van Hoof and Pennings, 2011; Van Hoof et al., 2015). Indeed, the European 
Court of Human Rights justified the use of CBRC within the EU as a way of 
circumventing national laws (European Court of Human Rights, 2010). Thus, 
the criticism of Zhang et al. (2017) for proceeding in this way is at best 
muted.  
 
Concluding remarks 
The first successful case of MRT provides hope for the future of this 
technique and no one will take note of this success more than the patients 
who have been waiting in anticipation for the science to find itself solidly 
grounded and for the law to catch up with the science. The scientific 
community would do well in fulfilling its obligations to society in general, 
and to these patients in particular, by acknowledging the achievement of 
Zhang and colleagues while noting their work’s shortcomings and providing 
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constructive criticism for the benefit of future cases. The editors of RBMO 
hope that the publication of this paper, together with this accompanying 
editorial, marks a positive step toward that goal.    
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